Latest / Stock Movers / Palantir Rises, Caterpillar Falls, Hims & Hers Drops on Earnings, Vertex Plunges on Drug Results
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news. The Stock Movers report,
- 0:10Speaker 1: your roundup of companies making moves in the stock market
- 0:13Speaker 1: harnessing the power of Bloomberg Data.
- 0:16Speaker 2: Let's take a look now at some of the individual
- 0:18Speaker 2: stocks on the move today. I'm Paul Sweeney alongside lismithte
- 0:21Speaker 2: and we're joined by Bloomberg's Tatiana Darier. Jenny. What are
- 0:24Speaker 2: you looking at today?
- 0:25Speaker 3: Well, Paul got to look a palanteer again. Up here
- 0:28Speaker 3: eight percent, the second largest mover in this MP five
- 0:31Speaker 3: hundred right now after reporting a forty eight percent surge
- 0:34Speaker 3: in revenue, and it was growth across segments revenue from government.
- 0:39Speaker 3: The government segment climbed fifty three percent above estimates. And
- 0:44Speaker 3: what analysts are most excited about, though, are the is
- 0:48Speaker 3: the commercial segment and growth there. That revenue has grown
- 0:52Speaker 3: by about ninety three percent for the year, and to
- 0:56Speaker 3: in analyst views, this is a key indicator of robust
- 0:59Speaker 3: demand for their AI systems. The stock here up eight percent,
- 1:04Speaker 3: up more than what now, one hundred and twenty percent.
- 1:07Speaker 3: Here today the fifth largest contributor to SMP five hundred gains,
- 1:12Speaker 3: So it's no longer just a retail favorite. This has
- 1:15Speaker 3: become a bigger force for the SMP five hundred as
- 1:18Speaker 3: a whole.
- 1:18Speaker 4: Well, yeah, especially with all their government contracts that you
- 1:20Speaker 4: were talking about, too huge for them. Okay, let's move
- 1:23Speaker 4: on to a Caterpillar because a lot of people look
- 1:25Speaker 4: at this. It's kind of like this bell weather for
- 1:27Speaker 4: the economy.
- 1:27Speaker 3: Exactly, a big macro name shares are pairing drop their
- 1:32Speaker 3: drop now they're about flat or slightly lowered by three
- 1:35Speaker 3: tenths of a percent, and miss Onypus results are tariffs
- 1:38Speaker 3: are biding into profitability. The company projected a net impact
- 1:43Speaker 3: from incremental tariffs of over a billion, somewhere between one
- 1:47Speaker 3: point three to one point five. Baired estimates that levees
- 1:50Speaker 3: are now dragging margins by about two hundred to three
- 1:54Speaker 3: hundred basis points. So that's why their guidance is coming
- 1:57Speaker 3: at the low end of their guidance of four margins
- 2:00Speaker 3: and even though they're projecting growth in their annual sales.
- 2:04Speaker 3: So that's kind of an interesting because it sort of
- 2:07Speaker 3: goes against what we've seen with the industrials, where analysts
- 2:10Speaker 3: are saying that they do retain some of the pricing power,
- 2:13Speaker 3: where for Caterpillar it doesn't appear to be the case.
- 2:16Speaker 2: Yeah, it's interesting. You would think if somebody would have
- 2:18Speaker 2: some pricing power would be somebody with a brand name
- 2:21Speaker 2: as strong as Caterpillar and a global name. But it's
- 2:24Speaker 2: impacting all types of companies here, hymns and hers, hims
- 2:29Speaker 2: and hers.
- 2:30Speaker 3: Interesting name saw a total reversal here over the past hour.
- 2:34Speaker 3: You know, it was down about fourteen percent. The pre
- 2:36Speaker 3: market now is about flat. Analysts and investors are reconsidering
- 2:41Speaker 3: their results. It posted a second quarter revenue miss and
- 2:45Speaker 3: sort of the weakness stems from their weight loss drug sales.
- 2:50Speaker 3: And you know, the story here is that this talk
- 2:52Speaker 3: has risen a lot more than one hundred and sixty
- 2:55Speaker 3: percent this year because they've been selling copycat versions of
- 2:59Speaker 3: the popular weight loss drugs from ili Le Novo Nordisk. Now,
- 3:03Speaker 3: the FDA came out earlier this year and said stop
- 3:06Speaker 3: selling copycats. We don't want them on the market.
- 3:08Speaker 2: I've never understood why they. I guess they allowed it
- 3:11Speaker 2: because the Zempics of the world were in a short supply,
- 3:15Speaker 2: so they allowed kind of these knockoffs to kind of
- 3:19Speaker 2: go to the market. Is that kind of what happened.
- 3:20Speaker 3: Exactly, Paul, They're they're in high demand everywhere, even abroad.
- 3:25Speaker 3: And now Jeffrey is saying that perhaps investors are overlooking
- 3:29Speaker 3: other positives in the numbers, like the second quarter even
- 3:32Speaker 3: a bit and the fact that they're going to launch
- 3:35Speaker 3: a hormonal health sort of are pivoting away from weight
- 3:39Speaker 3: loss to hormonal therapies and expanding into other places like Canada.
- 3:44Speaker 3: But I feel like my theory is that it just
- 3:46Speaker 3: goes up or palenteer here lifting all boats, you know,
- 3:50Speaker 3: weight loss, AI, all popular things.
- 3:53Speaker 4: Well, it's funny because they had that partnership with Novo
- 3:55Speaker 4: Nordis for a week, go v at the discount, and
- 3:58Speaker 4: then that just didn't work out very well for them.
- 4:01Speaker 3: No, not at all with the Novo Nordics. They're accusing
- 4:05Speaker 3: them of illegal mass compounding and quote, this is.
- 4:09Speaker 2: The best compounding, So these aren't. They're not trying to
- 4:13Speaker 2: think they're not knockoffs. Their compounds I think is the term.
- 4:17Speaker 2: And they kind of get you very very very close
- 4:20Speaker 2: to the original drope but.
- 4:21Speaker 4: Not all there.
- 4:22Speaker 3: Yeah, and price is key, right, it's more affordable in
- 4:25Speaker 3: a more accessible for people. Well, the next name here
- 4:30Speaker 3: in the health care space is a Vertex down about
- 4:34Speaker 3: seventeen percent. It has expanded extended losses here from the
- 4:40Speaker 3: pre market. The story there is that the FDA came
- 4:43Speaker 3: out and said that one of their paint pills doesn't
- 4:47Speaker 3: have or it doesn't see a path teacher for a
- 4:50Speaker 3: broad use in treating a certain type of chronic pain.
- 4:54Speaker 3: This is a big one for them because they've been
- 4:56Speaker 3: trying to pivot their business away from a systic fibrosis
- 4:59Speaker 3: and this is the first type of pinkiller to reach
- 5:02Speaker 3: the US market in more than two decades, so it's
- 5:05Speaker 3: a big one for them. They're studying it in various
- 5:07Speaker 3: different uses well for this particular use for chronic pain
- 5:13Speaker 3: costs for nerve damage. The FDA is saying that it
- 5:16Speaker 3: doesn't see a back forward, and that is knocking the
- 5:19Speaker 3: stock off here down seventeen percent. Ear Tickers vrtns.
- 5:23Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
- 5:28Speaker 1: us throughout the day for the latest roundup of companies
- 5:30Speaker 1: making news on Wall Street and for the latest market
- 5:33Speaker 1: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 5:38Speaker 1: Bloomberg dot com, and on Applecarplay and Android Auto with
- 5:41Speaker 1: the Bloomberg Business app.